ACADIA PharmaceuticalsMEX:ACAD 73 Days Payable is 42.57 as of Mar. 2026, which is 69% below its 10-year median of 136.16. GuruFocus rates MEX:ACAD with a GF Score™ of 73/100 and a GF Value™ of MXN357.71 (Fairly Valued). The stock has 9 warning signs investors should review. Among 706 Biotechnology companies, ACADIA Pharmaceuticals ranks worse than 61.33% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ACAD vs EWTX, CRNX, VKTX: Days Payable Comparison
For the Biotechnology subindustry, ACADIA Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ACADIA Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where ACADIA Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ACADIA Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ACADIA Pharmaceuticals (MEX:ACAD) has a Days Payable of 42.57 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ACADIA Pharmaceuticals and its competitors. This is 69% below median its historical median of 136.16. Over the past decade, ACADIA Pharmaceuticals' Days Payable has ranged from 55.56 to 352.25. According to the industry distribution chart, ACADIA Pharmaceuticals ranks #433 out of 706 companies in the Biotechnology industry, placing it in the top 61.3%.
Is ACADIA Pharmaceuticals' Days Payable too high?
ACADIA Pharmaceuticals' current Days Payable of 42.57 is 69% below median its 10-year median of 136.16. Over the past 10 years, this metric has ranged from a low of 55.56 to a high of 352.25. The Biotechnology industry median Days Payable is 113.56. ACADIA Pharmaceuticals' value of 42.57 is 62.5% below this industry median. Based on the distribution chart, ACADIA Pharmaceuticals ranks #433 out of 706 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ACADIA Pharmaceuticals has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Days Payable compare to EWTX and CRNX?
According to the Biotechnology industry distribution chart, ACADIA Pharmaceuticals ranks #433 out of 706 companies for Days Payable. This places ACADIA Pharmaceuticals in the lower half of its industry. The industry median Days Payable is 113.56. ACADIA Pharmaceuticals' value of 42.57 is 62.5% below this benchmark. Historically, ACADIA Pharmaceuticals' own Days Payable has ranged from 55.56 to 352.25 over the past decade. While the company's 10-year median is 136.16 vs. the industry median of 113.56, ACADIA Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.56, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ACADIA Pharmaceuticals's current Days Payable of 42.57 is 62.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ACADIA Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 113.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ACADIA Pharmaceuticals's current Days Payable is 42.57, which is 69% below median its own 10-year median of 136.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Fairly Valued. The stock's GF Value™ is MXN357.71, compared to a current price of MXN362.00 — trading 1.2% above its estimated fair value. The current Days Payable is 42.57, which is 69% below median its 10-year median of 136.16 and 62.5% below the Biotechnology industry median of 113.56. ACADIA Pharmaceuticals' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Days Payable is 42.57 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued.
The current stock price of MXN362.00 is trading 1.2% above its estimated GF Value™ of MXN357.71.
GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.
Key valuation signals for MEX:ACAD:
Days Payable: 42.57 (69% below median its 10-year median of 136.16)
GF Value™: MXN357.71 vs. price of MXN362.00 (1.2% above fair value)
Industry Position: 62.5% below the Biotechnology median (#433 of 706)
No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
73GF Score
Get the complete analysis for MEX:ACAD
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ACAD has been successfully added to your 
